Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brandy Eason

Nurse Practitioner, Family Little Rock, AR Nurse Practitioner

NPI 1548629199 CMS profile 11089687

9501 Baptist Health Dr Ste 900, Little Rock, AR 72205

Open in the dashboard

General payments

$12,588

756 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brandy Eason of Little Rock, AR is reported in the CMS Open Payments database as having received $12,588 across 756 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,765 188
2024 General $3,195 173
2023 General $2,490 117
2022 General $2,354 145
2021 General $1,784 133

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brandy Eason
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Brandy Eason were reported at $2,765. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Brandy Eason Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,784 $124 $35–$379 $132
2022 $2,354 $141 $44–$430 $149
2023 $2,490 $154 $49–$476 $160
2024 $3,195 $165 $51–$504 $164
2025 $2,765 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $4,038 235 payments
  2. Janssen Biotech, Inc. $1,356 70 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,171 86 payments
  4. Enterra Medical, Inc. $526 8 payments
  5. Gilead Sciences, Inc. $499 19 payments
  6. Ironwood Pharmaceuticals, Inc $464 56 payments
  7. Aimmune Therapeutics, Inc. $464 28 payments
  8. Regeneron Healthcare Solutions, Inc. $447 14 payments
  9. Pfizer Inc. $430 22 payments
  10. Phathom Pharmaceuticals, Inc. $364 37 payments
  11. Other $2,829 181 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,422 753 payments
  2. Education $167 3 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $1,594 96 payments
  2. XIFAXAN $1,122 81 payments
  3. STELARA $880 38 payments
  4. CREON $833 53 payments
  5. SKYRIZI $828 42 payments
  6. TREMFYA $736 37 payments
  7. LINZESS Gastroenterology $709 56 payments
  8. ZENPEP $709 56 payments
  9. HUMIRA $700 49 payments
  10. Linzess Gi $464 56 payments
  11. Other $5,512 351 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

459

Median for Nurse Practitioner: 389

Drug cost

$130,295

Median for Nurse Practitioner: $21,885

Branded share of claims

21.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 18 $50,889
Zenpep Lipase/Protease/Amylase Brand 12 $34,177
Linzess Linaclotide Brand 30 $23,027
Mounjaro Tirzepatide Brand 12 $12,440
Movantik Naloxegol Oxalate Brand 13 $5,193
Budesonide Dr Budesonide Brand 12 $1,246
Pantoprazole Sodium Generic 149 $1,019
Famotidine Generic 84 $680
Colestipol Hcl Generic 12 $510
Omeprazole Generic 47 $486

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$10,549

Medicare's payments for the services billed

Medicare patients

85

Average age 70

Services billed

164

55 women, 30 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Diabetes 33%
Depression 33%
Ischemic heart disease 32%
Osteoporosis 25%
COPD 21%
Chronic kidney disease 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $333
$333 — —
STELARA
  • Janssen Biotech, Inc. $307
$307 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $278
$278 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $240
$240 — —
SKYRIZI
  • AbbVie, Inc. $236
$236 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

756 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record